EU`s drug regulator again rejects Apellis` eye med and PTC`s Translarna
US FDA declines to approve Rocket Pharma`s immune disorder gene therapy
US FDA declines to approve Merck-Daiichi`s `guided missile` cancer drug
FDA rejects Merck`s first ADC in Daiichi partnership
Glenmark recalls 114 batches of low potassium drug in the US
J&J nixes Tremfya trial in giant cell arteritis
US FDA rejects AbbVie`s Parkinson`s disease therapy for the second time
G1 Therapeutics Fails Late-Stage Breast Cancer Trial
NEW DELHI: Biotechnology player Biocon on Saturday said the US health regulator has issued four observations after inspecting its manufacturing plant in Andhra Pradesh. The US Food and Drug Administration (USFDA) concluded a GMP inspection of the company's API facility (Site 5), located at Visakhapatnam, Andhra Pradesh, on June 21, 2024, the company said in a regulatory filing. nnRead more at: nhttps://economictimes.indiatimes.com/industry/healthcare/biotech/biocon-gets-4-observations-from-usfda-for-andhra-pradesh-facility/articleshow/111192847.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst